BELTSVILLE, Md., Oct. 02, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the promotion of Timothy Mayer, Ph.D. from Senior Vice President, Corporate Development to Chief Operating Officer.
“I am delighted to make this announcement. Tim joined NextCure at our inception and has contributed significantly to major NextCure achievements, including our alliance with Eli Lilly & Company and our recently completed initial public offering. He has played a pivotal role on the executive management team leading corporate development, strategy, and business operations and we are confident he will continue to be instrumental in the company’s success,” said Michael Richman, NextCure’s President and Chief Executive Officer. “I look forward to continuing to work with Tim at this important and exciting time in our company’s history.”
Dr. Mayer has extensive experience in the biopharmaceutical industry, including with antibody therapeutics, small molecule pharmaceuticals and molecular biology research tools. Prior to joining NextCure, he served in several positions at MacroGenics, a biopharmaceutical company focused on the treatment of cancer, where he oversaw all intellectual property matters, assisted with business development for various licensing transactions and helped facilitate MacroGenics’ initial public offering. Before MacroGenics, Dr. Mayer served in several positions at Banner & Witcoff, an intellectual property law firm, where he drafted and prosecuted biotech and pharmaceutical applications and conducted patentability and freedom-to-operate searches in all areas of biotechnology and small molecule chemistry. Dr. Mayer also worked on developing cloning systems while at Life Technologies and Invitrogen. He received his Ph.D. in Microbiology and Immunology from Penn State University College of Medicine and B.S. degrees in Microbiology and Biochemistry from California Polytechnic State University.
About NextCure, Inc.
NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Through our proprietary FIND-IO™ platform, we study various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. Our initial focus is to bring hope and new treatments to patients who do not respond to current cancer therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies. www.nextcure.com

